MSD India Chief On The Now, Next For Januvia, Gardasil And Keytruda’s Ascent
MSD India managing director Rehan Khan talks to Scrip about price adjustments for Januvia and the brand’s strong physician recall amid a tsunami of competition post loss of exclusivity, as also plans for Gardasil, which faces upcoming competition from Indian vaccines star Serum Institute. He also signals huge strides made by Keytruda, now the top cancer therapy in the country.
You may also be interested in...
HPV Vaccines – The Journey So Far And Long Road Ahead
HPV vaccines have come a long way since their launch in 2006, though not without their share of bumps and misinformation campaigns. US pediatric infectious disease specialist, Dr Kenneth Alexander, talks to Scrip about how data has evolved, why the US may not be the best example to emulate for HPV vaccination and new products on the horizon, among other topics.
'Brands Don’t Die': Cipla Grabs Rights To Novartis’ Galvus In India
Novartis draws up perpetual license agreement with Cipla for its vildagliptin brand in India. Experts weigh in on some deal nuances and whether the DPP-4 inhibitor can deliver long-term value in an ultra-competitive segment.
Five Big Pharma Products That Saw Action In India; There’s More To Come
Scrip spotlights the action around five key big pharma products in India. We track the gains made by Rybelsus and Keytruda, the wave of Januvia and Ibrance generics and on-market and court action for blockbuster Entresto.